MedTrace Logo

Trial of Modafinil for Methamphetamine Dependence

NCT00123370 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2007-05-01

No results posted yet for this study

Summary

The study aims to evaluate the safety and efficacy of modafinil (200 mg/day) over 10 weeks plus a tailored cognitive behavioural therapy program in the treatment of methamphetamine dependence.

Conditions

  • Amphetamine Dependence

Interventions

DRUG

Modafinil

Sponsors & Collaborators

  • Australian Government Department of Health and Ageing

    collaborator OTHER_GOV

  • Kirketon Road Centre, Sydney Hospital

    collaborator UNKNOWN

  • St Vincent's Hospital, Sydney

    collaborator OTHER

  • The University of New South Wales

    lead OTHER

Principal Investigators

  • Richard P Mattick, PhD · University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2007-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123370 on ClinicalTrials.gov